Our mission
Providing custom tailored, high quality preclinical services to prime your drugs for success.
WHY US
We offer expert solutions for optimal preclinical testing
- standardized efficacy evaluation platforms
- long standing expertise in preclinical testing
- humanized precision models
- unique animal models mimicking the complexity of human disease
- over 100 therapeutics successfully tested
- scientific excellence
LATEST NEWS & BLOG

Categories NewsPosted on
Biomedcode has developed these new humanized mice that develop spontaneous phenotypes including dermatitis lesions in jaw-neck area, ear thickening, enlarged draining lymph nodes, spleenomegaly etc.

Categories NewsPosted on
Biomedcode has been recognized by the Pharma Tech Outlook magazine as one of the top 10 CROs of the year 2020.

Categories PublicationsPosted on
Our new publication in Arthritis Research and Therapy presents a new mouse model recapitulating the specificity and complexity of human spondyloarthritis
PRECLINICAL SERVICES DELIVERED
114
CLIENTS
311
CONTRACTS
130
THERAPEUTICS TESTED
27
COUNTRIES

OUR CLIENTS SAY

"Our company had a pleasant experience of productive collaboration with Biomedcode s.a. in 2015. We would like to especially highlight the high quality of the study protocol preparation and report writing as well as efficient communication with Biomedcode’s CEO. We greatly appreciate your professionalism and looking forward to our future collaboration."
Biopharmaceutical company
Moscow, Russia
"We have several collaborations with Biomedcode, their scientific and efficient experiment schedules made each collaboration accomplished according to plan. From Biomedcode, we obtained convincing study reports and detailed records, which saved a lot of time for us in whole pre-clinical stage. We believe contracting professional works to such a professional and sophisticated group is a wise choice."

"It was a great pleasure working with Biomedcode that exhibited great expertise in preclinical testing and handled all the steps of the study with great professionalism always abiding by the terms of the agreement and always staying in close communication with us making this a very productive collaboration."
Biopharmaceutical company
Shanghai, China
"The authors acknowledge the role of BioMedCode relating to studies involving the human Tg197 TNF transgenic mouse model of polyarthritis in identifying sensitive study designs to optimally address efficacy comparability in this well-establish and characterized disease model"
Biopharmaceutical company
Germany
"…that was a pleasure to work with Biomedcode. Perfect in every aspect: study design, correspondence, preparation of the report, timing, additional discussions and etc. Biomedcode was recommended to us by the other company and after working with them we highly recommend Biomedcode to everyone."
Biopharmaceutical company
Moscow, RussiaClients
Research Funding

Categories PublicationsPosted on
Our new publication in Arthritis Research and Therapy presents a new mouse model recapitulating the specificity and complexity of human spondyloarthritis

Categories PublicationsPosted on
Our PLOS Computational Biology paper presents a new analytical approach that can serve as powerful tool to evaluate and compare arthritis treatments

Categories PublicationsPosted on
Biomedcode scientists coauthor a publication in Annals of Rheumatic diseases showing that Tg197 mice develop heart valve pathology sharing common...